Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

PD-1 related transcriptome profile and clinical outcome in diffuse gliomas

First author:Liu Shuai,Wang Zheng

Corresponding author:Qiu Xiaoguang,Jiang Tao

PD-1 RNA-seq checkpoint inhibitors glioma immunoth

essential_information

2017-10-25

Published articles

Journal:Oncoimmunology

Publication type: Original Research

IF(IF): 8.11

PMID: 29308304 Link To Pubmed Full text Download

Background And Purpose

Method

Through Chinese Glioma Genome Atlas and TCGA datasets, we systematically reviewed a total of 994 cases with RNA-seq data and analyzed the functional annotation of PD-1 by Gene ontology (GO) analysis. Univariate and multivariate survival analysis were performed in 907 patients with survival data.

Conclusion

Our results indicated that PD-1 was involved in key steps of anti-tumor immune process and independently predicted worse prognosis in diffuse gliomas. These findings may expend our understanding of potential anti-PD-1 treatments.

Main results

We found PD-1 was significantly upregulated in glioblastoma and isocitrate dehydrogenase wild type tumors. According to TCGA transcriptional classification scheme, PD-1 expression was higher in tumors of mesenchymal subtype than other subtypes, and shown good predictive value to mesenchymal subtype. GO analysis revealed that genes significantly correlated with PD-1 were involved in essential functions associated with anti-tumor immune process. Through screening transcriptomic data, we found a strong correlation between PD-1 and immune cell populations especially for T cells. In addition, we investigated the association between PD-1 and genes related to its function, and found that PD-1 was significantly correlated with genes including TGFB1, IDO1, CD40, ICOS and SATB1, and other immune checkpoint molecules including CTLA4, LAG3, TIM3 and CD276. Survival analysis suggested that higher PD-1 expression was independently associated with worse prognosis of patients with diffuse gliomas.